Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

ClinicalTrials.gov ID: NCT01009463

Public ClinicalTrials.gov record NCT01009463. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

HZC102871: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)

Study identification

NCT ID
NCT01009463
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,626 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 25, 2009 (Type not available)
Primary completion
Oct 1, 2011 (Actual)
Completion
Oct 31, 2011 (Actual)
Last update posted
Nov 9, 2017

2009 – 2011

United States locations

U.S. sites
94
U.S. states
32
U.S. cities
88
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35235 —
GSK Investigational Site Birmingham Alabama 35294 —
GSK Investigational Site Jasper Alabama 35501 —
GSK Investigational Site Peoria Arizona 85381 —
GSK Investigational Site Phoenix Arizona 85012 —
GSK Investigational Site Phoenix Arizona 85050 —
GSK Investigational Site Scottsdale Arizona 85258 —
GSK Investigational Site Chula Vista California 91911 —
GSK Investigational Site Lincoln California 95648 —
GSK Investigational Site Long Beach California 90822 —
GSK Investigational Site Los Angeles California 90048 —
GSK Investigational Site Mission Viejo California 92691 —
GSK Investigational Site Palo Alto California 94304 —
GSK Investigational Site Poway California 92064 —
GSK Investigational Site Rancho Mirage California 92270 —
GSK Investigational Site Riverside California 92506 —
GSK Investigational Site Rolling Hills Estates California 90274 —
GSK Investigational Site Santa Monica California 90404 —
GSK Investigational Site Sepulveda California 91343 —
GSK Investigational Site Torrance California 90503 —
GSK Investigational Site Stamford Connecticut 06902 —
GSK Investigational Site Bay Pines Florida 33744 —
GSK Investigational Site Clearwater Florida 33755 —
GSK Investigational Site Clearwater Florida 33756 —
GSK Investigational Site Fort Myers Florida 33916 —
GSK Investigational Site Gainesville Florida 32608 —
GSK Investigational Site Miami Florida 33136 —
GSK Investigational Site Orlando Florida 32822 —
GSK Investigational Site Ormond Beach Florida 32174 —
GSK Investigational Site Tamarac Florida 33321 —
GSK Investigational Site Winter Park Florida 32792 —
GSK Investigational Site Austell Georgia 30106 —
GSK Investigational Site Decatur Georgia — —
GSK Investigational Site Lawrenceville Georgia 30046 —
GSK Investigational Site Belleville Illinois 62220 —
GSK Investigational Site River Forest Illinois 60305 —
GSK Investigational Site Avon Indiana 46123 —
GSK Investigational Site Lafayette Indiana 47904 —
GSK Investigational Site Muncie Indiana 47304-5547 —
GSK Investigational Site Newburgh Indiana 47630 —
GSK Investigational Site Iowa City Iowa 52242 —
GSK Investigational Site Lenexa Kansas 66215 —
GSK Investigational Site Wichita Kansas 67205 —
GSK Investigational Site Munfordville Kentucky 42765 —
GSK Investigational Site Owensboro Kentucky 42301 —
GSK Investigational Site New Orleans Louisiana 70115 —
GSK Investigational Site Sunset Louisiana 70584 —
GSK Investigational Site Columbia Maryland 21044 —
GSK Investigational Site Saint Joseph Michigan 49085 —
GSK Investigational Site Southfield Michigan 48034 —
GSK Investigational Site Minneapolis Minnesota 55402 —
GSK Investigational Site Minneapolis Minnesota 55407 —
GSK Investigational Site Plymouth Minnesota 55441 —
GSK Investigational Site Saint Charles Missouri 63301 —
GSK Investigational Site Billings Montana 59102 —
GSK Investigational Site Lebanon New Hampshire 03756 —
GSK Investigational Site Ocean City New Jersey 7712 —
GSK Investigational Site New York New York 10004 —
GSK Investigational Site New York New York 10029 —
GSK Investigational Site Elizabeth City North Carolina 27909 —
GSK Investigational Site Salisbury North Carolina 28144 —
GSK Investigational Site Dayton Ohio 45406 —
GSK Investigational Site Oklahoma City Oklahoma 73103 —
GSK Investigational Site Oklahoma City Oklahoma 73120 —
GSK Investigational Site Tulsa Oklahoma 74136-8303 —
GSK Investigational Site Medford Oregon 97504 —
GSK Investigational Site Sellersville Pennsylvania 18960 —
GSK Investigational Site Johnston Rhode Island 02919 —
GSK Investigational Site Anderson South Carolina 29621 —
GSK Investigational Site Charleston South Carolina 29406-7108 —
GSK Investigational Site Chester South Carolina 29706 —
GSK Investigational Site Gaffney South Carolina 29340 —
GSK Investigational Site Greenwood South Carolina 29646 —
GSK Investigational Site Greer South Carolina 29651 —
GSK Investigational Site Seneca South Carolina 29678 —
GSK Investigational Site Chattanooga Tennessee 37421 —
GSK Investigational Site New Tazewell Tennessee 37824-1409 —
GSK Investigational Site Austin Texas 78705 —
GSK Investigational Site Boerne Texas 78006 —
GSK Investigational Site Fort Worth Texas 76109 —
GSK Investigational Site Kingwood Texas 77339 —
GSK Investigational Site Lake Jackson Texas 77566 —
GSK Investigational Site San Antonio Texas 78229 —
GSK Investigational Site Temple Texas 76508 —
GSK Investigational Site South Burlington Vermont 05403 —
GSK Investigational Site Abingdon Virginia 24210 —
GSK Investigational Site Charlottesville Virginia 22911 —
GSK Investigational Site Fredericksburg Virginia 22401 —
GSK Investigational Site Richmond Virginia 23225 —
GSK Investigational Site Virginia Beach Virginia 23455 —
GSK Investigational Site Lakewood Washington 98499 —
GSK Investigational Site Spokane Washington 99204 —
GSK Investigational Site Tacoma Washington 98405 —
GSK Investigational Site Wenatchee Washington 98801 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 94 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01009463, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 9, 2017 · Synced Oct 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01009463 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →